Early access programs (EAP) provide unauthorized medicinal products prior to marketing authorization and commercial launch for life-threatening, chronically or seriously debilitating diseases, which can not be treated satisfactorily by an authorized medicinal product. Legislation is mostly at the national level, and practical aspects such as conduct, sponsorship, permission to charge for the medicinal product, and data collection frequently differ per country. Organizers must also consider differing national medical practices and standards of care.
This poster aims to review current status and challenges associated with mechanisms governing the provision of unlicensed pharmaceutical compounds in areas of high unmet need outside of clinical trials and provides recommendations for avoiding common pitfalls based on review of actual case studies in selected markets.
Jean-Luc Béjot, Senior Medical Director; Emmanuel Prades, Director, Clinical Operations; Daniel Muscionico, Chief Operating Officer; Adeline Darchy, Clinical Project Manager; Voisin Consulting Life Sciences.
May 2017 - 22nd Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Jean-Luc Béjot, Vice President Corporate Strategy
As Vice President, Corporate Strategy Jean-Luc works closely with the CEO and the Executive Committee at VCLS to drive the company’s mid- to long-term growth and evolution. In this role, he leads the initiative to evaluate new trends in the life sciences arena and where applicable, to translate them into new business opportunities. He is also responsible for the coordination of acquisitions and partnerships, and the identification and management of major corporate risks. Before becoming VP, Jean-Luc was responsible for creating and growing the Clinical Operations Group at VCLS.
Emmanuel Prades, Senior Director, Clinical & Vigilance Operations
After 22 years in many diverse clinical research departments, in both pharmaceutical and medical device industries, Emmanuel has significant experience in the management of international clinical studies (all phases) from protocol writing to reporting. He also has experience in overall project management, Clinical Quality Assurance, pre-market vigilance for Medical Device and coordination of multiple functional teams and subcontractors.
Daniel Muscionico, Chief Operating Officer
Daniel has accumulated over 20 years of management experience, with Profit & Loss responsibility, in the life science industry, specializing in financial services, risk management and information security. He is also a senior lecturer in the fields of healthcare economics and public health at the Institute of Global Health, Geneva Faculty of Medicine, where he earned his Doctor of Pharmacy degree.